Friday, 13th February 38th Lorne Cancer Conference 2026

• Application of spatial transcriptomics and deep learning to identify immunotherapy resistance - James s Wilmott
• Emerging Cytokine Therapies for Cancer  - Nicholas D Huntington
• T cell homing to tumours: a critical requirement for cancer immunotherapy success - Lisa M Ebert
• Genomic evolution in preinvasive lung disease in TRACERx - Clare Puttick
• Venetoclax and azacitidine induced damage to the bone marrow vasculature significantly impacts engraftment of highly primitive donor derived haematopoietic stem cells.   - Steven Ngo

Session Sponsors

• Targeting Chromatin Complexes in Cancer - Scott Armstrong
• Precision Medicine in Acute Lymphoblastic Leukaemia … new targets/new approaches?   - Deborah White
• Clonal memories and clonal destiny - Shalin H Naik
• Uncovering the in vivo dynamics of blood cancer cell death and clearance in the bone marrow microenvironment post-therapy - Georgia Atkin-Smith
• Integrating venetoclax sensitivity profiling and high-throughput drug screening to inform personalised therapy in paediatric acute myeloid leukaemia - Mehrin Zaman

Session Sponsor

• Deciphering stem cell roles in driving GI tract Cancers - Nick Barker
• Horizontal DNA transfer in transmissible cancer - Elizabeth Murchison
• Pro-oncogenic remodelling of fibroblasts by Apc mutant epithelial cells supports intestinal tumour initiation and growth - Thierry Jarde
• The New Cartography: Spatial Biology’s Future Routes - Jared Burks

Session Sponsor

• Integrative spatial multi-omics and 3-dimensional reconstruction resolves mechanisms of glioma invasion - Joel JD Moffet
• Decoding epigenetic mechanisms of Acute Myeloid Leukemia (AML) relapse through The Clone Claw: a single-cell platform for isolating and profiling rare MRD clones - Kelsy Prest
• p300/CBP co-ordinate with the metazoan INO80 complex in haematological malignancies, providing synthetic lethal opportunities.  - Oliver Sinclair
• Investigating the role of mRNA transcript diversity in therapy-induced plasticity in melanoma - Lorey Smith
• A novel PKCδ molecular switch drives chemoresistance in triple-negative breast cancer - Vishnu Sunil Jaikumar
• Rb-Driven Transcriptional Programs Counteract Its Tumour Suppressor Function in Luminal Breast Cancer - April C Watt

Poster Presentation Schedule (200-299):

  Odd Poster Numbers: 5:30pm - 6:30pm
  Even Poster Numbers: 6:30pm - 7:30pm

Flash Talk Posters

Integrative spatial multi-omics and 3-dimensional reconstruction resolves mechanisms of glioma invasion - Joel JD Moffet (#200)

Decoding epigenetic mechanisms of Acute Myeloid Leukemia (AML) relapse through The Clone Claw: a single-cell platform for isolating and profiling rare MRD clones - Kelsy Prest (#201)

p300/CBP co-ordinate with the metazoan INO80 complex in haematological malignancies, providing synthetic lethal opportunities.  - Oliver Sinclair (#202)

Investigating the role of mRNA transcript diversity in therapy-induced plasticity in melanoma - Lorey Smith (#203)

A novel PKCδ molecular switch drives chemoresistance in triple-negative breast cancer - Vishnu Sunil Jaikumar (#204)

Rb-Driven Transcriptional Programs Counteract Its Tumour Suppressor Function in Luminal Breast Cancer - April C Watt (#205)

Poster Presentations

• Establishment of patient-derived models of metastatic appendiceal cancers - King Ho Leong
• Advancing Plasma Proteomics: Olink, Nanoparticle Enrichment, and Soluble HLA Profiling for Precision Biomarker Discovery - Terry Lim
• Beyond the androgen receptor; a reprogramming framework identifies novel master-regulator networks driving aggressive prostate cancer lineage - Natalie L Lister
• 50-marker multiplexed imaging transforms the potential of circulating tumor cells to guide precision oncology - John G Lock
• Deep multiplex immunofluorescence of DNA damage response identifies targetable synthetically lethal interactions - Timothy J. Mann
• Deciphering ovarian cancer origins in the fallopian tube - Laura Marruecos
• Retrospective single cell lineage tracing with expressed somatic mitochondrial variants - Cal McCrimmon
• Breast cancer risk factors and Pik3ca mutations promote expansion of estrogen receptor positive luminal progenitors   - Conor McGuinness
• Defining the role of the immune system in early breast cancer - Sarah McLucas
• Translational reprogramming disrupts mitosis to drive SMAD4-deficient oesophageal adenocarcinoma - Julia Milne
• Evaluating PTEN mutations as a predictor of response to combinatorial therapy in ovarian cancer - Leean Miranda
• Development of novel cellular models to investigate the biological mechanism of breast cancer polygenic risk. - Ashleigh Monson
• Peroxisome Biology in IDH1 Mutated Cancer: Mechanisms and Targetable Vulnerabilities   - MAHTA MORAGHEBI
• Loss of tristetraprolin drives the progression to treatment resistant prostate cancer by altering stress response pathways - Katherine L Morel
• Tryptophan metabolism fuels one-carbon metabolism and regulates serine synthesis in triple-negative breast cancer: A novel druggable pathway - Jamshid Motalebzadeh
•   BCL6 as driver of glioma with insights from a GEM-CLeM model system - Naychi Myo Min
• RUNX1 and beyond: genetic mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukaemia - Zuhal ZN Naderi
• AMPK drives metabolic adaptation and resistance to KRAS inhibition in pancreatic cancer - David M Nash
• DUSP4 copy loss: an alternate mediator of ERK/MAPK signaling activation and a novel driver of colorectal cancer - Kristen A Needham
• Investigating the heterogeneity of acute myeloid leukaemia response to different classes of therapy using lineage tracing. - Daniel Neville
• Optimising a Decellularized Bovine Scaffold Model for Culturing Bone Metastases and Drug Screening - Holly Newman
• Suppressing vasculogenic mimicry in claudin-low breast cancer by targeting Neuropilin-1 - Ngoc Minh Long Nguyen
• Haematopoietic stem cell derived CAR-T cells for improved anticancer immunity - Phillip Nguyen
• NRF2 co-opts the SWI/SNF complex to drive liver cell plasticity - Athena Jessica S Ong
• ChemProTarget: A Cancer-Agnostic Pipeline Linking Undruggable Cancer Vulnerabilities to On-Target Covalent Small Molecules - John Paul Ong
• Mitochondrial DNA Mutations Are Associated with Impaired Mitochondrial Fitness and TKI Sensitivity in CML - Ilaria Stefania Pagani
• Genomic complexity and adaptive alterations underpin drug resistance in myeloid blast crisis chronic myeloid leukaemia cell lines - Ilaria Stefania Pagani
• Temporally resolved proteomics identifies nidogen-2 as a co-target in pancreatic cancer that modulates fibrosis and therapy response - Brooke Pereira
• Mini-Tumours, Major Impact: Patient-derived breast tumour organoids for precision medicine - Yohanka Perera
• Harnessing phosphoproteomic profiling for target discovery in high-risk osteosarcoma: A pathway to novel therapies? - Callum M Perkins
• Rationalising the inclusion of HDAC inhibitors with standard-of-care chemotherapy for high-risk neuroblastoma - Monica Phimmachanh
• Determining the role of autophagy in p-PKCδ mediated chemoresistance in triple negative breast cancer - Emily Phipps
• Characterising genomic heterogeneity in KRAS-mutant lung adenocarcinoma - Siddharth Pruthi
• Clonal heterogeneity of drug tolerant persisters following targeted therapy in non-small cell lung cancer - Sunniyat Rahman
• Targeting a redox protein, thioredoxin reductase 3, sensitizes triple-negative breast cancers to EGFR inhibitors. - Prahlad Raninga
• Extracellular vesicle-associated miRNA biomarkers improve the early detection of ovarian cancer - Gregory E Rice
• Pancreatic cancer secretome reveals PCSK9 as a co-target to sensitise tumours to chemotherapy and reduce metastasis - Shona Ritchie
• Expanding the utility of PARP inhibitors using combination therapy with androgen receptor signalling inhibitors in prostate cancer - Mahsa Rostamiandelavar
• Dissecting the tumour-neural microenvironment in prostate cancer - Lauren Ryan
• Targeting the nucleoli as a strategy to treat ovarian cancer - Elaine Sanij
• Testing the efficacy of Neuropilin-1 inhibition in pre-clinical models of claudin-low breast cancer   - Samar Sanjabi
• Using human and bioengineered skin to elucidate mechanisms in melanocyte and melanoma subpopulations that drive cancer initiation and progression - Adriana Sanna
• Investigating the role of clusterin in platinum-treated ovarian cancer - Jessica Scott
• Prioritizing PI3K pathway inhibitors for PTEN-mutant breast cancer - Kaveesha Senasinghe
• FGFR2 spatial isoforms in tumour progression and prognosis, and emerging novel target in endometrial cancer precision therapy - Asmerom T Sengal
•   Extracellular Vesicles as Drivers of Tumor-Microenvironment Crosstalk in Oral Cancer - Adnan AS Shafiq
• Genomic guided therapies in oesophageal adenocarcinoma - Sowmya L Sharma
• Targeted CDK4/6 inhibition to improve outcomes in triple negative breast cancer - Hasha Simad
• Interrogating the immune microenvironment changes during breast cancer development using multiple genetically engineered mouse models - Xiaoyu (Shirley) Song
• Identifying drugs that boost immunogenicity of prostate cancer bone metastases via high-throughput screening - Aliye Tabatabaee
• Clinical candidate drug NXP800 inhibits HSF1 pathway and activates the Integrated Stress Response (ISR) via GCN2 in ARID1A mutant ovarian cancer - Maria E Taskinen
• Investigating transcript diversity as a driver of melanoma progression and metastasis using nanopore long-read RNA sequencing - Jun Yao Teow
• CHK1 inhibitor with low dose Hydroxyurea Amplifies Replication Stress and Drives a Novel Pan-nuclear Ataxia Telangiectasia Mutated Phenotype - Max J Thompson
• Precision mRNA-LNP therapeutics for cancer - Hannah Tompkins
• Identifying and targeting treatment response mechanisms to improve Gemcitabine/Abraxane performance in Patient-Derived Models of Pancreatic Cancer - Alice Tran
• Optimising CUT&RUN to Dissect the Role of FOXA1 in the Normal Breast: Binding Patterns in ER+ Luminal Progenitor Cells. - Ella R Treherne
• Targeting macrophage-specific vulnerabilities to reduce relapse following AML differentiation therapy. - Jake H Tremewen
• Pinpointing and targeting novel drivers of pancreatic cancer progression and metastasis using TRAP-seq - Michael Trpceski
• Investigating therapeutically targetable mechanisms of SNAI1-driven Acute Myeloid Leukaemia. - Lynda LT Truong
• Co-targeting thrombospondin-1 (THBS-1) to improve KRAS inhibitor and chemotherapeutic efficacy in pancreatic cancer - Victoria M Tyma
• Cell cycle inhibition promotes Natural Killer cell-mediated cytotoxicity against colorectal liver metastasis organoids - Robin Wagner
• Temporal single clone analyses reveal a Xlr4b driven HSPC program that facilitates T-cell reconstitution following transplantation. - Elanor N Wainwright
• An intronic AR responsive region of ZBTB16 but not ZBTB16 itself is critical for AR mediated tumour suppression in ER positive breast cancer - Maliha Wajahat
• Y box binding protein 1 mediated modulation of chromosomal instability in cancer - Selena Wang
• Investigating therapy-induced isoform-switching in melanoma using CRISPR-Cas13. - Naomi Warren
• Angiotensin converting enzyme-2 suppresses cancer growth in mice with a secondary liver cancer - Muditha N Wijesinghe
• Thyroid hormone receptor beta as a Metabolic Driver in triple-negative breast cancer: Implications for the clinical use of TRβ agonists. - Andrew J. Woo
• Targeting tumour fibrosis with a small molecule ROCK2 inhibitor to improve radiotherapy response in head and neck cancer - Dannel Yeo
• Unleashing the analytical potential of ovarian ascites via deep multiplexed imaging - Ye (Gloria) Zheng